Table 1.

Patient characteristics

	Patient #1	Patient #2	Patient #3
Disease duration [years]	6	5	6
Medication [years]	Donepezile 10 mg [3] Donepezile 5 mg [1] Gingko 240 mg [0.25] Mirtazapine 30 mg [3]	Rivastigmine 9.5 mg [2] Citalopram 20 mg [0.75]	Rivastigmine 9.5 mg [2] Gingko 240 mg [0.5]
Severity of dementia	Mild AD, MMSE 27	Mild AD, MMSE 22	Moderate AD, MMSE 17
Clinical course	Slowly progressive with an increase of progression over the past year	Slowly progressive	Slowly progressive
Cognitive deficits	Encoding/consolidation memory, spatial and temporal orientation, executive functions	Encoding/consolidation memory, spatial and temporal orientation, visoconstructional skills	Encoding/consolidation memory, spatial and temporal orientation, visoconstructional skills, language, apraxia
MRI	Mild bilateral hippocampal atrophy	Moderate bitemporal atrophy including hippocampal atrophy	Global cortical atrophy
CSF	Amyloid beta ↓ Phosphorylated tau levels ↑	Amyloid beta ↓ Phosphorylated tau levels ↑	Amyloid beta ↓ Phosphorylated tau levels →